Safety Reading Notes

Read safety context beside the research guide.

The GPR18 cannabinoid target source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 32365486

PubMed For Dummies Article

GPR18 cannabinoid target Evidence Review: the long-form source walk-through

Quick read
  • GPR18 cannabinoid target currently has 19 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 32365486
  • The evidence classes most visible in the row language are mechanistic or pharmacological (12), and insufficient (7). PMID 28826536
  • The study-design language most visible in the row language is Narrative or expert review (7), Cellular or in vitro study (7), and Animal study (4). PMID 27835801
  • The repeated topics are GPR18 (19), which tells the reader where to start opening PubMed and DOI links. PMID 34676329

Start with the research question

GPR18 cannabinoid target is built from 19 source-backed evidence row(s) and 19 research source(s). The current evidence classes read as mechanistic or pharmacological (12), and insufficient (7), and the study-design language most often reads as Narrative or expert review (7), Cellular or in vitro study (7), and Animal study (4). PMID 32365486

The row-level question is not simply whether GPR18 cannabinoid target is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are GPR18 (19). PMID 28826536

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 42114685

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 29902723

Mechanistic evidence 12 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 24762058

Limits and uncertainty 7 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 40562148

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 29098189

Where this page has the most source density

The largest bucket surfaced for this page is GPR18: mechanistic or pharmacological. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is GPR18: insufficient, which gives readers another way to see what the literature repeatedly circles. PMID 32365486

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 28826536

Bucket chapters: what the literature is circling

GPR18: mechanistic or pharmacological

12 research sources 12 rows (946-962) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on GPR18: mechanistic or pharmacological. It currently draws from 12 research source(s), so the exact study type matters. PMID 32365486

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 32365486

  • Evidence row 946

    THC modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, si... PMID 32365486

  • Evidence row 962

    CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: GPR18 receptor activity, binding, signaling, or ph... PMID 24751709

GPR18: insufficient

7 research sources 7 rows (944-961) Evidence class: insufficient

This bucket summarizes source-backed rows focused on GPR18: insufficient. It currently draws from 7 research source(s), so the exact study type matters. PMID 28826536

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 28826536

  • Evidence row 944

    Cannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling,... PMID 28826536

  • Evidence row 961

    Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 18187165

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (12 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 32365486

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 28826536

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 27018161
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 30871175
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 20346144

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 32365486

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 28826536

Source-reading checklist for GPR18 cannabinoid target

  1. Open the linked PubMed or DOI record. PMID 22834922
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 21595653
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 29138268
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 23461720
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 24431468

Source Notes

GPR18 cannabinoid target source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 944

    Cannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 28826536

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.
  2. Evidence row 945

    Cannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 27835801

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor ligand bias: implications in the central nervous system.
  3. Evidence row 946

    THC modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 32365486

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Computational Investigations on the Binding Mode of Ligands for the Cannabinoid-Activated G Protein-Coupled Receptor GPR18.
  4. Evidence row 947

    Endocannabinoids modulates GPR18; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 34676329

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in Gynecological Diseases.
  5. Evidence row 948

    Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 42114685

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders.
  6. Evidence row 949

    THC modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 29902723

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18.
  7. Evidence row 950

    THC modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 24762058

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Activation of GPR18 by cannabinoid compounds: a tale of biased agonism.
  8. Evidence row 951

    Cannabinoids modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 40562148

    Evidence class: mechanistic or pharmacological. Source: Structural insights into the activation of G protein-coupled receptor 119 by the agonist GSK1292263 and ligands selectivity among novel cannabinoid receptors.
  9. Evidence row 952

    Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 29098189

    Evidence class: insufficient; Study design: Narrative or expert review. Source: An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors.
  10. Evidence row 953

    Endocannabinoids modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 27018161

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine.
  11. Evidence row 954

    Endocannabinoids modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 30871175

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Protective Effect of N-Arachidonoyl Glycine-GPR18 Signaling after Excitotoxical Lesion in Murine Organotypic Hippocampal Slice Cultures.
  12. Evidence row 955

    CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 20346144

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor.
  13. Evidence row 956

    CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 22834922

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: siRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycine-induced cell migration.
  14. Evidence row 957

    THC modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 21595653

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells.
  15. Evidence row 958

    Endocannabinoids modulates GPR18; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 29138268

    Evidence class: insufficient; Study design: Narrative or expert review. Source: N-Acyl Amino Acids (Elmiric Acids): Endogenous Signaling Molecules with Therapeutic Potential.
  16. Evidence row 959

    CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 23461720

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: A GPR18-based signalling system regulates IOP in murine eye.
  17. Evidence row 960

    CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 24431468

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The novel endocannabinoid receptor GPR18 is expressed in the rostral ventrolateral medulla and exerts tonic restraining influence on blood pressure.
  18. Evidence row 961

    Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 18187165

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The elmiric acids: biologically active anandamide analogs.
  19. Evidence row 962

    CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 24751709

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature.